GT Biopharma, Inc.
$0.37
▲
9.79%
2026-04-21 07:12:01
www.gtbiopharma.com
NCM: GTBP
Explore GT Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$11.72 M
Current Price
$0.37
52W High / Low
$3.85 / $0.35
Stock P/E
—
Book Value
$0.23
Dividend Yield
—
ROCE
-214.65%
ROE
-13.77%
Face Value
—
EPS
$-6.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
1.2
Debt / Equity
—
Current Ratio
3.5
Quick Ratio
3.5
Forward P/E
-0.03
Price / Sales
—
Enterprise Value
$4.83 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$3
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 2. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 3. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
| 4. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 5. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 6. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 7. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.59 M | -3.38 M | -1.51 M | -1.93 M | -3.76 M | — |
| Net Profit | -23.03 M | 8.3 M | -30.17 M | -0.78 M | -3.77 M | — |
| EPS in Rs | -0.73 | 0.26 | -0.96 | -0.02 | -0.12 | -1.53 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -12.42 M | -14.36 M | -13.58 M | -21.26 M |
| Net Profit | -28.35 M | -13.16 M | -7.6 M | -20.88 M |
| EPS in Rs | -0.9 | -0.42 | -0.24 | -0.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.11 M | 4.23 M | 14.11 M | 16.74 M |
| Total Liabilities | 2.32 M | 5.9 M | 6.63 M | 5 M |
| Equity | 5.79 M | -1.67 M | 7.48 M | 11.73 M |
| Current Assets | 8.11 M | 4.23 M | 14.06 M | 16.56 M |
| Current Liabilities | 2.32 M | 5.9 M | 6.63 M | 4.94 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.91 M | -12.9 M | -8.85 M | -15.22 M |
| Investing CF | 0 M | 12.89 M | -2.01 M | 12.14 M |
| Financing CF | 15.78 M | 2.98 M | 6.27 M | -0.22 M |
| Free CF | -12.91 M | -12.9 M | -8.85 M | -15.22 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -73.25% | 63.62% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-02-05 | 1:0.0333333 |